Key points from article :
In a bid to enhance its personalized health offerings, AI-powered consumer health platform Hundred Health has acquired BellSant, a wellness company grounded in longevity research. The all-stock deal aims to integrate BellSant’s deep scientific insights into Hundred’s subscription-based service, which analyses over 115 biomarkers using wearable data and artificial intelligence to help users optimize their health. The service costs $499 per year—a price point now standard in this emerging sector, also charged by competitors like Function Health and Superpower.
Hundred Health stands out by turning complex data into personalized, easy-to-understand narratives rather than simply presenting raw medical results. BellSant’s scientific foundation—built on research from top institutions including Johns Hopkins, Harvard, and Stanford—adds predictive models in genomics, metabolism, sleep, and brain health to the platform. These models will be integrated into Hundred’s AI engine to offer even more precise and personalized health insights.
The deal also brings new talent: BellSant founder Matt Fellowes joins Hundred’s advisory board, and key engineers and data scientists from BellSant will now work under the Hundred umbrella. The acquisition comes just as Hundred wraps up a closed beta and prepares for a full-scale launch this summer, with over 50,000 people already on the waitlist. Although the article doesn’t cite a scientific journal or lead author, it underscores the growing interest in AI-backed longevity platforms that combine cutting-edge science with user-friendly healthcare tools.
